Ryplazim Injection, Powder, Lyophilized, For Solution
NDC 70573-099
Product Information
Ryplazim (plasminogen) is a BLA-approved product labeled by Kedrion Biopharma, Inc.. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a injection, powder, lyophilized, for solution for intravenous administration. This product entry covers the primary NDC 70573-099 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 70573-099?
What are the uses of this product?
What are Active Ingredients of this product?
- PLASMINOGEN 68.8 mg/1 - Precursor of plasmin (FIBRINOLYSIN). It is a single-chain beta-globulin of molecular weight 80-90,000 found mostly in association with fibrinogen in plasma; plasminogen activators change it to fibrinolysin. It is used in wound debriding and has been investigated as a thrombolytic agent.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- PLASMINOGEN (UNII: 1EF190B6M7)
- PLASMINOGEN (UNII: 1EF190B6M7) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- SUCROSE (UNII: C151H8M554)
- GLYCINE (UNII: TE7660XO1C)
- SODIUM CITRATE, UNSPECIFIED FORM (UNII: 1Q73Q2JULR)
- SODIUM CHLORIDE (UNII: 451W47IQ8X)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2557205 - plasminogen, human-tvmh 68.8 MG Injection
- RxCUI: 2557210 - Ryplazim 68.8 MG Injection
- RxCUI: 2557210 - plasminogen, human-tvmh 68.8 MG Injection [Ryplazim]
* Please review the full disclaimer at the bottom of this page.